Skip to content

Commit 0385941

Browse files
dongzhenyedongzhenye
authored
Merge pull request #4 from dongzhenye/feat/initial-data
数据：初始化100种常见原研药
2 parents 8999d1d + 50a3d0f commit 0385941

99 files changed

Lines changed: 5009 additions & 0 deletions

Some content is hidden

Large Commits have some content hidden by default. Use the searchbox below for content that may be hidden.

‎data/10.md‎

Lines changed: 50 additions & 0 deletions
Original file line numberDiff line numberDiff line change
@@ -0,0 +1,50 @@
1+
---
2+
id: 10
3+
registrationType: 境外生产药品
4+
genericName: 利拉鲁肽
5+
productName: 利拉鲁肽注射液
6+
productNameEn: Liraglutide Injection
7+
brandName: 诺和力
8+
brandNameEn: Victoza
9+
category: 化学药品
10+
formulation: 注射剂
11+
specification: 18mg/3ml
12+
registrationNumber: 国药准字HJ20140256
13+
mahName: Novo Nordisk A/S
14+
mahAddress: Novo Alle, DK-2880 Bagsvaerd, Denmark
15+
manufacturerName: Novo Nordisk A/S
16+
manufacturerAddress: Novo Alle, DK-2880 Bagsvaerd, Denmark
17+
manufacturerCountry: 丹麦
18+
packagingName: 诺和诺德（中国）制药有限公司
19+
packagingAddress: 天津经济技术开发区第七大街71号
20+
approvalDate: 2014-08-20
21+
isOriginal: true
22+
originator: Novo Nordisk A/S
23+
originatorSource:
24+
- type: FDA橙皮书
25+
url: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=022341
26+
- type: 企业年报
27+
url: https://www.novonordisk.com/investors/financial-results.html
28+
originalException: "原研企业授权天津工厂分装"
29+
---
30+
31+
## 适应症
32+
33+
1. 成人2型糖尿病的治疗
34+
2. 与其他降糖药物联合使用
35+
3. 体重管理
36+
37+
## 注意事项
38+
39+
1. 甲状腺髓样癌家族史患者禁用
40+
2. 注意胰腺炎风险
41+
3. 定期监测血糖
42+
4. 需要冷链储存运输
43+
44+
## 不良反应
45+
46+
- 恶心、呕吐
47+
- 腹泻
48+
- 食欲减退
49+
- 注射部位反应
50+
- 低血糖

‎data/100.md‎

Lines changed: 51 additions & 0 deletions
Original file line numberDiff line numberDiff line change
@@ -0,0 +1,51 @@
1+
---
2+
id: 100
3+
registrationType: 境外生产药品
4+
genericName: 沙美特罗/丙酸氟替卡松
5+
productName: 沙美特罗/丙酸氟替卡松吸入气雾剂
6+
productNameEn: Salmeterol/Fluticasone Propionate Inhalation Aerosol
7+
brandName: 舒利迭
8+
brandNameEn: Seretide
9+
category: 化学药品
10+
formulation: 吸入气雾剂
11+
specification: 50μg/250μg
12+
registrationNumber: 国药准字HJ20210389
13+
mahName: GlaxoSmithKline Trading Services Limited
14+
mahAddress: 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
15+
manufacturerName: Glaxo Wellcome Production
16+
manufacturerAddress: Zone Industrielle No.2, 23 Rue Lavoisier, 27000 Evreux, France
17+
manufacturerCountry: 法国
18+
packagingName: 葛兰素史克制药（苏州）有限公司
19+
packagingAddress: 江苏省苏州工业园区苏虹东路200号
20+
approvalDate: 2021-12-30
21+
isOriginal: true
22+
originator: GlaxoSmithKline plc
23+
originatorSource:
24+
- type: FDA橙皮书
25+
url: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=021254
26+
- type: 企业年报
27+
url: https://www.gsk.com/en-gb/investors/corporate-reporting/annual-report/
28+
originalException: "原研企业授权苏州工厂分装"
29+
---
30+
31+
## 适应症
32+
33+
1. 支气管哮喘的维持治疗
34+
2. 慢性阻塞性肺疾病的维持治疗
35+
3. 预防运动诱发的支气管痉挛
36+
4. 改善肺功能
37+
38+
## 注意事项
39+
40+
1. 不用于急性症状的缓解
41+
2. 监测肾上腺功能
42+
3. 注意骨密度降低风险
43+
4. 避免突然停药
44+
45+
## 不良反应
46+
47+
- 口腔念珠菌病
48+
- 声音嘶哑
49+
- 头痛
50+
- 心动过速
51+
- 肌肉痉挛

‎data/11.md‎

Lines changed: 50 additions & 0 deletions
Original file line numberDiff line numberDiff line change
@@ -0,0 +1,50 @@
1+
---
2+
id: 11
3+
registrationType: 境外生产药品
4+
genericName: 恩格列净
5+
productName: 恩格列净片
6+
productNameEn: Empagliflozin Tablets
7+
brandName: 恩格卡
8+
brandNameEn: Jardiance
9+
category: 化学药品
10+
formulation: 片剂
11+
specification: 10mg
12+
registrationNumber: 国药准字HJ20170458
13+
mahName: Boehringer Ingelheim International GmbH
14+
mahAddress: Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
15+
manufacturerName: Boehringer Ingelheim Pharma GmbH & Co. KG
16+
manufacturerAddress: Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
17+
manufacturerCountry: 德国
18+
packagingName: 上海勃林格殷格翰药业有限公司
19+
packagingAddress: 上海市浦东新区外高桥保税区基隆路18号
20+
approvalDate: 2017-12-08
21+
isOriginal: true
22+
originator: Boehringer Ingelheim
23+
originatorSource:
24+
- type: FDA橙皮书
25+
url: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=204629
26+
- type: 企业年报
27+
url: https://www.boehringer-ingelheim.com/about-us/corporate-profile
28+
originalException: "原研企业授权上海工厂分装"
29+
---
30+
31+
## 适应症
32+
33+
1. 2型糖尿病的治疗
34+
2. 降低心血管死亡风险
35+
3. 降低慢性心力衰竭住院风险
36+
37+
## 注意事项
38+
39+
1. 肾功能不全患者需调整剂量
40+
2. 注意尿路感染和生殖道感染风险
41+
3. 监测血压和血容量状态
42+
4. 老年患者注意脱水风险
43+
44+
## 不良反应
45+
46+
- 尿路感染
47+
- 女性生殖道感染
48+
- 低血压
49+
- 血容量减少
50+
- 低血糖

‎data/12.md‎

Lines changed: 50 additions & 0 deletions
Original file line numberDiff line numberDiff line change
@@ -0,0 +1,50 @@
1+
---
2+
id: 12
3+
registrationType: 境外生产药品
4+
genericName: 达格列净
5+
productName: 达格列净片
6+
productNameEn: Dapagliflozin Tablets
7+
brandName: 安达唐
8+
brandNameEn: Forxiga
9+
category: 化学药品
10+
formulation: 片剂
11+
specification: 10mg
12+
registrationNumber: 国药准字HJ20160345
13+
mahName: AstraZeneca AB
14+
mahAddress: SE-151 85 Södertälje, Sweden
15+
manufacturerName: AstraZeneca Pharmaceuticals LP
16+
manufacturerAddress: 4601 Highway 62 East, Mount Vernon, IN 47620, USA
17+
manufacturerCountry: 美国
18+
packagingName: 无锡阿斯利康制药有限公司
19+
packagingAddress: 江苏省无锡市新区新畅南路2号
20+
approvalDate: 2016-09-28
21+
isOriginal: true
22+
originator: AstraZeneca PLC
23+
originatorSource:
24+
- type: FDA橙皮书
25+
url: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=202293
26+
- type: 企业年报
27+
url: https://www.astrazeneca.com/investor-relations/annual-reports.html
28+
originalException: "原研企业授权无锡工厂分装"
29+
---
30+
31+
## 适应症
32+
33+
1. 2型糖尿病的治疗
34+
2. 慢性肾脏病的治疗
35+
3. 慢性心力衰竭的治疗
36+
37+
## 注意事项
38+
39+
1. 肾功能不全患者需调整剂量
40+
2. 注意尿路感染和生殖道感染风险
41+
3. 监测血压和血容量状态
42+
4. 注意酮症酸中毒风险
43+
44+
## 不良反应
45+
46+
- 尿路感染
47+
- 外阴阴道炎
48+
- 低血压
49+
- 血容量减少
50+
- 血脂异常

‎data/13.md‎

Lines changed: 50 additions & 0 deletions
Original file line numberDiff line numberDiff line change
@@ -0,0 +1,50 @@
1+
---
2+
id: 13
3+
registrationType: 境外生产药品
4+
genericName: 伊马替尼
5+
productName: 伊马替尼片
6+
productNameEn: Imatinib Tablets
7+
brandName: 格列卫
8+
brandNameEn: Gleevec
9+
category: 化学药品
10+
formulation: 片剂
11+
specification: 100mg
12+
registrationNumber: 国药准字HJ20130045
13+
mahName: Novartis Pharma Schweiz AG
14+
mahAddress: Suurstoffi 14, 6343 Rotkreuz, Switzerland
15+
manufacturerName: Novartis Pharma Stein AG
16+
manufacturerAddress: Schaffhauserstrasse, 4332 Stein, Switzerland
17+
manufacturerCountry: 瑞士
18+
packagingName: 北京诺华制药有限公司
19+
packagingAddress: 北京市昌平区科技园区生命园路8号
20+
approvalDate: 2013-03-21
21+
isOriginal: true
22+
originator: Novartis AG
23+
originatorSource:
24+
- type: FDA橙皮书
25+
url: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=021588
26+
- type: 企业年报
27+
url: https://www.novartis.com/investors/financial-data/annual-reports
28+
originalException: "原研企业授权北京工厂分装"
29+
---
30+
31+
## 适应症
32+
33+
1. 费城染色体阳性慢性髓性白血病
34+
2. 胃肠道间质瘤
35+
3. 急性淋巴细胞白血病
36+
37+
## 注意事项
38+
39+
1. 定期监测血常规
40+
2. 监测肝肾功能
41+
3. 注意心脏毒性
42+
4. 妊娠期禁用
43+
44+
## 不良反应
45+
46+
- 水肿
47+
- 恶心呕吐
48+
- 骨髓抑制
49+
- 肝功能异常
50+
- 皮疹

‎data/14.md‎

Lines changed: 49 additions & 0 deletions
Original file line numberDiff line numberDiff line change
@@ -0,0 +1,49 @@
1+
---
2+
id: 14
3+
registrationType: 境外生产药品
4+
genericName: 厄洛替尼
5+
productName: 厄洛替尼片
6+
productNameEn: Erlotinib Tablets
7+
brandName: 特罗凯
8+
brandNameEn: Tarceva
9+
category: 化学药品
10+
formulation: 片剂
11+
specification: 150mg
12+
registrationNumber: 国药准字HJ20140167
13+
mahName: F. Hoffmann-La Roche Ltd.
14+
mahAddress: Grenzacherstrasse 124, 4070 Basel, Switzerland
15+
manufacturerName: Delpharm Milano S.r.l.
16+
manufacturerAddress: Via Carnevale, 1, 20054 Segrate (MI), Italy
17+
manufacturerCountry: 意大利
18+
packagingName: 上海罗氏制药有限公司
19+
packagingAddress: 上海市浦东新区龙东大道1100号
20+
approvalDate: 2014-06-18
21+
isOriginal: true
22+
originator: F. Hoffmann-La Roche Ltd.
23+
originatorSource:
24+
- type: FDA橙皮书
25+
url: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=021743
26+
- type: 企业年报
27+
url: https://www.roche.com/investors/annual-report
28+
originalException: "原研企业授权Delpharm生产，委托上海工厂分装"
29+
---
30+
31+
## 适应症
32+
33+
1. 表皮生长因子受体（EGFR）突变阳性的局部晚期或转移性非小细胞肺癌
34+
2. 胰腺癌的一线治疗
35+
36+
## 注意事项
37+
38+
1. 监测肝功能
39+
2. 注意间质性肺病风险
40+
3. 定期进行眼科检查
41+
4. 避免吸烟
42+
43+
## 不良反应
44+
45+
- 皮疹
46+
- 腹泻
47+
- 食欲减退
48+
- 疲劳
49+
- 间质性肺病

‎data/15.md‎

Lines changed: 54 additions & 0 deletions
Original file line numberDiff line numberDiff line change
@@ -0,0 +1,54 @@
1+
---
2+
id: 15
3+
registrationType: 境外生产药品
4+
genericName: 贝伐珠单抗
5+
productName: 贝伐珠单抗注射液
6+
productNameEn: Bevacizumab Injection
7+
brandName: 安维汀
8+
brandNameEn: Avastin
9+
category: 生物制品
10+
formulation: 注射剂
11+
specification: 100mg/4ml
12+
registrationNumber: 国药准字HJ20140223
13+
mahName: F. Hoffmann-La Roche Ltd.
14+
mahAddress: Grenzacherstrasse 124, 4070 Basel, Switzerland
15+
manufacturerName: Roche Diagnostics GmbH
16+
manufacturerAddress: Sandhofer Strasse 116, 68305 Mannheim, Germany
17+
manufacturerCountry: 德国
18+
packagingName: 上海罗氏制药有限公司
19+
packagingAddress: 上海市浦东新区龙东大道1100号
20+
approvalDate: 2014-07-12
21+
isOriginal: true
22+
originator: F. Hoffmann-La Roche Ltd.
23+
originatorSource:
24+
- type: FDA橙皮书
25+
url: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=125085
26+
- type: 企业年报
27+
url: https://www.roche.com/investors/annual-report
28+
originalException: "原研企业授权上海工厂分装"
29+
---
30+
31+
## 适应症
32+
33+
1. 转移性结直肠癌
34+
2. 晚期非小细胞肺癌
35+
3. 复发性胶质母细胞瘤
36+
4. 转移性乳腺癌
37+
5. 晚期或转移性肾细胞癌
38+
39+
## 注意事项
40+
41+
1. 注意出血风险
42+
2. 监测血压
43+
3. 注意伤口愈合并发症
44+
4. 需要冷链储存运输
45+
5. 避免手术前后使用
46+
47+
## 不良反应
48+
49+
- 高血压
50+
- 蛋白尿
51+
- 出血
52+
- 胃肠道穿孔
53+
- 血栓栓塞
54+
- 伤口愈合延迟

0 commit comments

Comments
 (0)